Epigenomics AG
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.
Epigenomics AG (EPGNF) - Net Assets
Latest net assets as of June 2025: $0.00 USD
Based on the latest financial reports, Epigenomics AG (EPGNF) has net assets worth $0.00 USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.86 Million) and total liabilities ($11.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $0.00 |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -391.01% |
| 10-Year Change | -258.42% |
| Growth Volatility | 130.38 |
Epigenomics AG - Net Assets Trend (2003–2024)
This chart illustrates how Epigenomics AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Epigenomics AG (2003–2024)
The table below shows the annual net assets of Epigenomics AG from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-11.24 Million | -40.28% |
| 2023-12-31 | $-8.02 Million | -178.80% |
| 2022-12-31 | $10.17 Million | -54.01% |
| 2021-12-31 | $22.12 Million | +472.46% |
| 2020-12-31 | $3.86 Million | -59.87% |
| 2019-12-31 | $9.63 Million | -48.27% |
| 2018-12-31 | $18.61 Million | +75.98% |
| 2017-12-31 | $10.58 Million | -26.67% |
| 2016-12-31 | $14.42 Million | +103.21% |
| 2015-12-31 | $7.10 Million | +16.21% |
| 2014-12-31 | $6.11 Million | -5.43% |
| 2013-12-31 | $6.46 Million | +55.34% |
| 2012-12-31 | $4.16 Million | -74.31% |
| 2011-12-31 | $16.19 Million | -48.28% |
| 2010-12-31 | $31.30 Million | +158.98% |
| 2009-12-31 | $12.08 Million | -27.06% |
| 2008-12-31 | $16.57 Million | -7.03% |
| 2007-12-31 | $17.82 Million | -37.38% |
| 2006-12-31 | $28.46 Million | -27.72% |
| 2005-12-31 | $39.38 Million | -17.52% |
| 2004-12-31 | $47.74 Million | +169.51% |
| 2003-12-31 | $17.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Epigenomics AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1637.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $907.89K | % |
| Other Comprehensive Income | $11.24 Million | % |
| Other Components | $79.78 Million | % |
| Total Equity | $-11.24 Million | 100.00% |
Epigenomics AG Competitors by Market Cap
The table below lists competitors of Epigenomics AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BEACN Wizardry & Magic Inc
V:BECN
|
$492.08K |
|
CELANESE-A (DG3.SG)
STU:DG3
|
$492.73K |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
$492.91K |
|
Bowler Metcalf Ltd
JSE:BCF
|
$493.42K |
|
Xali Gold Corp
PINK:CGDXF
|
$491.02K |
|
LEUCADIA NATIONAL
BE:LN3
|
$490.92K |
|
PGIM Short Duration High Yield ETF
BATS:PSH
|
$490.51K |
|
Lisi SA
STU:LI3
|
$490.15K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Epigenomics AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -8,015,703 to -11,244,559, a change of -3,228,856.
- Net loss of 3,470,057 reduced equity.
- Other comprehensive income decreased equity by 65,343,133.
- Other factors increased equity by 65,584,334.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.47 Million | -30.86% |
| Other Comprehensive Income | $-65.34 Million | -581.11% |
| Other Changes | $65.58 Million | +583.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Epigenomics AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $54.71 | $0.79 | x |
| 2004-12-31 | $90.32 | $0.79 | x |
| 2005-12-31 | $62.71 | $0.79 | x |
| 2006-12-31 | $40.39 | $0.79 | x |
| 2007-12-31 | $26.10 | $0.79 | x |
| 2008-12-31 | $16.61 | $0.79 | x |
| 2009-12-31 | $10.80 | $0.79 | x |
| 2010-12-31 | $100.96 | $0.79 | x |
| 2011-12-31 | $47.86 | $0.79 | x |
| 2012-12-31 | $13.40 | $0.79 | x |
| 2013-12-31 | $15.41 | $0.79 | x |
| 2014-12-31 | $12.77 | $0.79 | x |
| 2015-12-31 | $11.81 | $0.79 | x |
| 2016-12-31 | $20.27 | $0.79 | x |
| 2017-12-31 | $13.01 | $0.79 | x |
| 2018-12-31 | $21.62 | $0.79 | x |
| 2019-12-31 | $40.54 | $0.79 | x |
| 2020-12-31 | $13.12 | $0.79 | x |
| 2021-12-31 | $39.47 | $0.79 | x |
| 2022-12-31 | $12.51 | $0.79 | x |
| 2023-12-31 | $-9.39 | $0.79 | x |
| 2024-12-31 | $-12.82 | $0.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Epigenomics AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-85.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 37.88% | 62.26% | 0.34x | 1.77x | $4.94 Million |
| 2004 | 22.99% | 138.38% | 0.15x | 1.12x | $6.20 Million |
| 2005 | 22.32% | 91.60% | 0.21x | 1.14x | $4.85 Million |
| 2006 | -58.79% | -439.55% | 0.12x | 1.15x | $-18.02 Million |
| 2007 | -73.79% | -512.31% | 0.11x | 1.29x | $-14.93 Million |
| 2008 | -74.06% | -474.52% | 0.13x | 1.22x | $-13.93 Million |
| 2009 | -84.60% | -239.98% | 0.26x | 1.35x | $-11.43 Million |
| 2010 | -36.67% | -642.19% | 0.05x | 1.08x | $-14.61 Million |
| 2011 | -96.23% | -1083.86% | 0.07x | 1.20x | $-17.19 Million |
| 2012 | -293.41% | -1173.92% | 0.15x | 1.65x | $-12.61 Million |
| 2013 | -114.74% | -466.69% | 0.14x | 1.72x | $-8.06 Million |
| 2014 | -144.96% | -587.52% | 0.13x | 1.85x | $-9.46 Million |
| 2015 | -126.58% | -431.56% | 0.17x | 1.77x | $-9.69 Million |
| 2016 | -77.38% | -265.67% | 0.23x | 1.26x | $-12.60 Million |
| 2017 | -96.77% | -549.09% | 0.09x | 1.87x | $-11.29 Million |
| 2018 | -68.19% | -827.92% | 0.07x | 1.17x | $-14.55 Million |
| 2019 | -176.76% | -1512.89% | 0.08x | 1.45x | $-17.98 Million |
| 2020 | -302.43% | -1387.89% | 0.12x | 1.76x | $-12.07 Million |
| 2021 | -10.98% | -39.14% | 0.25x | 1.11x | $-4.64 Million |
| 2022 | -118.21% | -2479.18% | 0.03x | 1.56x | $-13.04 Million |
| 2023 | 0.00% | -1315.79% | 0.03x | 0.00x | $-3.66 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.35 Million |
Industry Comparison
This section compares Epigenomics AG's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $482,684,274
- Average return on equity (ROE) among peers: -68.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Epigenomics AG (EPGNF) | $0.00 | 37.88% | N/A | $491.44K |
| Agilent Technologies Inc (A) | $4.16 Billion | 9.64% | 0.80x | $31.54 Billion |
| Amer Bio Medica (ABMC) | $2.66 Million | -28.23% | 1.26x | $3.55K |
| ADCNF (ADCNF) | $852.85 Million | 37.00% | 2.65x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $2.00 Million |
| ANGLE plc (ANPCF) | $3.82 Million | -94.09% | 0.43x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.29K |
| Avricore Health Inc (AVCRF) | $-37.20K | 0.00% | 0.00x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $3.76 Million | -397.87% | 1.13x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $52.50 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $5.08 Million |